<DOC>
	<DOCNO>NCT02247401</DOCNO>
	<brief_summary>This study evaluate efficacy safety ABT-450/r/ABT-267 RBV treatment naive treatment experience HCV GT4 subject without compensate cirrhosis .</brief_summary>
	<brief_title>Coadministration ABT-450/Ritonavir/ABT-267 ( ABT-450/r/ABT-267 ) With Ribavirin ( RBV ) Adults With Genotype 4 ( GT4 ) Hepatitis C Virus ( HCV ) Egypt</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic hepatitis C , genotype 4infection ( HCV RNA level great 1,000 IU/mL Screening ) Subjects must meet one follow : Treatmentnaive : Subject never receive antiviral treatment hepatitis C infection OR Treatment Experienced ( Prior null responder , Partial responder Relapsers pegIFN/RBV ) ; Females must postmenopausal , nonchild bear potential practicing specific form birth control In substudy 1 , demonstrate absence liver cirrhosis confirm liver biopsy Fibroscan In substudy 2 , evidence liver cirrhosis confirm liver biopsy Fibroscan ChildPugh score less equal 6 Screening confirm absence hepatocellular carcinoma Females pregnant breastfeed Positive screen hepatitis B Surface antigen antiHuman Immunodeficiency virus antibody HCV genotype perform screen indicate unable genotype coinfection HCV genotype abnormal laboratory test selfreports current drinking 2 drink per day current enrollment another investigational study previous treatment direct act antiviral agent ( DAA ) contain regimen In substudy 1 , evidence liver cirrhosis In substudy 2 , evidence current past ChildPugh B C classification confirm presence hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non-responder</keyword>
	<keyword>Egypt</keyword>
	<keyword>HCV</keyword>
	<keyword>null responder</keyword>
	<keyword>Genotype 4</keyword>
	<keyword>compensate cirrhosis</keyword>
	<keyword>naive</keyword>
	<keyword>treatment experience</keyword>
	<keyword>hepatitis c</keyword>
	<keyword>relapser</keyword>
	<keyword>hepatitis infection</keyword>
	<keyword>partial responder</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>